Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
- 8 January 2010
- journal article
- clinical trial
- Published by Elsevier BV in Vaccine
- Vol. 28 (3), 849-857
- https://doi.org/10.1016/j.vaccine.2009.10.017
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Current status and progress of prepandemic and pandemic influenza vaccine developmentExpert Review of Vaccines, 2009
- MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly AdultsPLOS ONE, 2009
- Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1New England Journal of Medicine, 2008
- An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy AdultsThe Journal of Infectious Diseases, 2008
- Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trialVaccine, 2008
- Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in AdultsThe Journal of Infectious Diseases, 2008
- Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza VaccinePLOS ONE, 2008
- Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trialThe Lancet, 2007
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006
- Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) VaccineNew England Journal of Medicine, 2006